Company Expects Filing as Early as Today
PraXsyn Name Change Has Been Filed With the State of Illinois and Soon to be Filed With FINRA
PALO ALTO, Calif., April 17, 2014 (GLOBE NEWSWIRE) -- The PAWS Pet Company, Inc. (OTCQB:PAWS), announces that its 10K filing has been delayed by some unforeseen issues due to its recent merger. "Although we pushed to the extreme to get the 10K filed on time, last minute issues and our desire to be completely accurate and fully complete, got the better of us," said Dan Wiesel, CEO of The PAWS Pet Company.
The company expects to have the 10K filed as early as today.
On the bright side, we can announce that we have filed the paperwork with the State of Illinois to change the company's name to PraXsyn, Inc. and will be using the new name on the 10K filing. We will also be filing name change paperwork shortly with FINRA.
Our goal at the new PraXsyn to is provide medical practitioners with products and services to help them help their patients. Our Mesa Pharmacy division currently provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. Mesa has developed a series of topical ointments, in different strengths, that provide the pain relief doctors seek.
About PraXsyn, Inc.
PraXsyn, Inc. is dedicated to providing medical practitioners with medications and services for their patients. We currently formulate transdermal creams and ointments in our compounding pharmacy, Mesa Pharmacy. These are geared to patients suffering from long-term pain associated with work place related injuries. In the near future, we will be instituting our Point of Care/In-Office Dispensing Program, and our In-Office Toxicology Testing. As the medical industry changes, PraXsyn will be there to provide different delivery systems.
For additional information go to www.praxsyn.com
Company Contact: email@example.com
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.